000908572 001__ 908572
000908572 005__ 20240708133739.0
000908572 0247_ $$2doi$$a10.1093/neuonc/noz126.264
000908572 0247_ $$2ISSN$$a1522-8517
000908572 0247_ $$2ISSN$$a1523-5866
000908572 0247_ $$2WOS$$aWOS:000493085900266
000908572 037__ $$aFZJ-2022-02696
000908572 082__ $$a610
000908572 1001_ $$0P:(DE-Juel1)159312$$aBauer, E. K.$$b0$$ufzj
000908572 1112_ $$a14th Meeting of the European Association of Neuro-Oncology$$cLyon$$d2019-09-19 - 2019-09-22$$wFrance
000908572 245__ $$aP14.29 Prediction of overall survival in patients with malignant glioma using dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine PET
000908572 260__ $$c2019
000908572 3367_ $$0PUB:(DE-HGF)1$$2PUB:(DE-HGF)$$aAbstract$$babstract$$mabstract$$s1657289123_28844
000908572 3367_ $$033$$2EndNote$$aConference Paper
000908572 3367_ $$2BibTeX$$aINPROCEEDINGS
000908572 3367_ $$2DRIVER$$aconferenceObject
000908572 3367_ $$2DataCite$$aOutput Types/Conference Abstract
000908572 3367_ $$2ORCID$$aOTHER
000908572 520__ $$aAbstractBACKGROUNDCharacterization of gliomas according to the revised World Health Organization (WHO) classification of 2016 has gained major importance regarding prognostication. The present study aimed at exploring the prognostic value of dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET in newly diagnosed and molecularly defined astrocytic high-grade glioma (HGG) of the WHO grades III or IV.MATERIAL AND METHODSBefore initiation of treatment, dynamic FET PET imaging was performed in patients with newly diagnosed glioblastoma (GBM) and anaplastic astrocytoma (AA). Static FET PET parameters such as maximum and mean tumor/brain ratios (TBRmax/mean), as well as the dynamic FET PET parameters time-to-peak (TTP) and slope, were obtained. The predictive ability of FET PET parameters was evaluated with regard to the overall survival (OS). Using ROC analyses, threshold values for FET PET parameters were obtained. Subsequently, univariate Kaplan-Meier and multivariate Cox regression survival analyses were performed to assess their predictive power for OS.RESULTSSixty patients (45 GBM, 15 AA) of two university centers were retrospectively identified. Patients with a methylated MGMT promoter as well as with an IDH mutation had a significantly longer OS (both P<0.001). Furthermore, ROC analysis revealed in IDH-wildtype HGG (n=45) that a TTP>25 minutes (AUC, 0.90; sensitivity, 90%; specificity, 87%; P<0.001) was highly prognostic for a longer OS (29 vs. 12 months; P<0.001). Besides a complete resection and a methylated MGMT promoter, TTP remained significant in the multivariate survival analysis (P=0.002, P=0.016, and P=0.003, respectively), indicating an independent predictor for OS. In contrast, both TBRmax and TBRmean were not prognostic (AUC, 0.37 and 0.32, respectively).CONCLUSIONData suggest that within the subgroup of patients with newly diagnosed and untreated IDH-wildtype GBM and AA, dynamic FET PET additionally allows the identification of patients with an improved OS.
000908572 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x0
000908572 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000908572 7001_ $$0P:(DE-Juel1)131627$$aStoffels, G.$$b1$$ufzj
000908572 7001_ $$0P:(DE-HGF)0$$aBlau, T.$$b2
000908572 7001_ $$0P:(DE-HGF)0$$aReifenberger, G.$$b3
000908572 7001_ $$aWerner, J. M.$$b4
000908572 7001_ $$0P:(DE-Juel1)145110$$aLohmann, P.$$b5$$ufzj
000908572 7001_ $$0P:(DE-HGF)0$$aRapp, M.$$b6
000908572 7001_ $$0P:(DE-Juel1)131720$$aFink, G. R.$$b7$$ufzj
000908572 7001_ $$0P:(DE-Juel1)131777$$aLangen, K.$$b8$$ufzj
000908572 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, N.$$b9$$ufzj
000908572 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noz126.264$$gVol. 21, no. Supplement_3, p. iii73 - iii73$$x1523-5866$$y2019
000908572 909CO $$ooai:juser.fz-juelich.de:908572$$pVDB
000908572 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)159312$$aForschungszentrum Jülich$$b0$$kFZJ
000908572 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131627$$aForschungszentrum Jülich$$b1$$kFZJ
000908572 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145110$$aForschungszentrum Jülich$$b5$$kFZJ
000908572 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b7$$kFZJ
000908572 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b8$$kFZJ
000908572 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b9$$kFZJ
000908572 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000908572 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-02-03$$wger
000908572 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-02-03
000908572 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-02-03
000908572 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-02-03
000908572 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-02-03
000908572 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-03
000908572 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-02-03
000908572 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-03
000908572 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-02-03
000908572 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2019$$d2021-02-03
000908572 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bNEURO-ONCOLOGY : 2019$$d2021-02-03
000908572 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x0
000908572 9201_ $$0I:(DE-Juel1)IEK-5-20101013$$kIEK-5$$lPhotovoltaik$$x1
000908572 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x2
000908572 980__ $$aabstract
000908572 980__ $$aVDB
000908572 980__ $$aI:(DE-Juel1)INM-4-20090406
000908572 980__ $$aI:(DE-Juel1)IEK-5-20101013
000908572 980__ $$aI:(DE-Juel1)INM-3-20090406
000908572 980__ $$aUNRESTRICTED
000908572 981__ $$aI:(DE-Juel1)IMD-3-20101013